A new class of subtype-selective muscarinic acetylcholine (mACh) receptor agonist that activates the receptor through interaction at a site distinct from the orthosteric acetylcholine binding site has been reported recently. Here, we have compared the effects of orthosteric (oxotremorine-M, arecoline, pilocarpine) and allosteric
prevented the orthosteric agonist-induced adaptive changes in receptor populations; however, in contrast, the copresence of atropine and AC-42 significantly increased both cell-surface receptor and total M 1 mACh receptor expression. Maximal phosphoinositide hydrolysis responses to the partial agonist arecoline were similar in CHO-M 1 cells pretreated for 24 h with either AC-42 or vehicle; in contrast, these responses were markedly reduced when cells were pretreated with oxotremorine-M or pilocarpine. These data indicate that, whereas AC-42 binding to the M 1 mACh receptor can initiate signal transduction, the AC-42-liganded receptor is resistant to the usual mechanisms regulating receptor internalization and down-regulation. In addition, our data suggest unusual interactions between allosteric agonists and orthosteric antagonists to regulate cell-surface and total cellular receptor expression.
Muscarinic acetylcholine (mACh) receptors are G proteincoupled receptors (GPCRs) responsible for the metabotropic actions of the neurotransmitter acetylcholine. Five mACh receptor subtypes, M 1 to M 5 , have been identified in humans and other mammals, with the M 1 /M 3 /M 5 subtypes coupling preferentially to G q/11 proteins, leading to the activation of the phospholipase C/inositol 1,4,5-trisphosphate (IP 3 )/Ca 2ϩ signaling pathway, and the M 2 /M 4 subtypes coupling to G i/o proteins and inhibition of adenylyl cyclase activity (Caulfield and Birdsall, 1998) . The mACh receptors are widely distributed throughout the periphery and central nervous system, and have been implicated as potential therapeutic targets in an array of diseases, including chronic obstructive pulmonary disease, irritable bowel syndrome, Alzheimer's disease, and schizophrenia (see Eglen et al., 1999; Felder et al., 2000; Langmead et al., 2008b) .
A major obstacle in the development of successful cholinergic therapies has been the lack of mACh receptor subtypespecific ligands, and the potentially serious side-effect profile of agents that interact with multiple mACh receptor subtypes (Bymaster et al., 1998; Eglen et al., 1999; Bartolomeo et al., 2000) . The high degree of sequence conservation among the amino acid residues that form the orthosteric binding pocket is likely to account for the difficulty in discovering subtype-selective drugs (Hulme et al., 2003) . An alternative approach is to target allosteric binding sites on mACh receptors, which are likely to be less well conserved than critical orthosteric ligand binding sites within the transmembrane core (Hulme et al., 2003; Gregory et al., 2007) . This has resulted in a new generation of subtype-selective mACh receptor ligands that either modulate or stimulate specific receptors in a highly subtype-selective manner (Spalding et al., 2002; Jones et al., 2008; Shirey et al., 2008; Ma et al., 2009; Marlo et al., 2009) .
In addition to offering the potential for mACh receptor subtype-specific effects, allosteric agonists may stabilize distinct receptor conformations, relative to orthosterically directed ligands, and therefore instigate a distinct repertoire of receptor signaling and receptor regulatory properties. Indeed, we have recently reported that the M 1 mACh receptor allosteric agonists, AC-42 and 77-LH-28-1, activate a subtly different subset of G proteins compared with equi-efficacious orthosteric ligands (Thomas et al., 2008) . Although attention has so far focused on the acute signaling effects and diseasemodifying potential of the M 1 mACh receptor allosteric agonists, little is presently known about the receptor-regulatory actions of this new class of receptor-active agent. Such information is vital if the ultimate aim is to develop these agents for clinical application. It is well established that prolonged exposure of GPCRs to orthosteric agonists results in a reduction in receptor-mediated responses through regulatory mechanisms that involve phosphorylation, G protein uncoupling, internalization, and down-regulation (Wess, 1996; Ferguson, 2001; van Koppen and Kaiser, 2003) , whereas, at least under some circumstances, inverse agonists can up-regulate receptor expression (Smit et al., 1996; Milligan and Bond, 1997; Dowling et al., 2006) . The effects of allosteric ligands on GPCR regulation are poorly defined at present and appear to be receptor subtype-specific. Thus, previous work exploring long-term exposure to allosteric modulators of the M 2 mACh receptor revealed an up-regulation of receptor numbers (May et al., 2005) , whereas chronic exposure to AC260584, an allosteric agonist structurally related to AC-42 (Spalding et al., 2002) , resulted in no significant changes in M 1 mACh receptor expression (Davis et al., 2005) . In contrast, and looking beyond the mACh receptor subfamily, activation of the type 7 metabotropic glutamate receptor by the allosteric agonist AMN082 caused receptor internalization in a manner similar to that elicited by the orthosteric ligand, L-AP4 (Pelkey et al., 2007) . Here, we have compared the regulatory effects of longer-term exposure to allosteric versus orthosteric agonists on M 1 mACh receptor internalization, downregulation, and signal transduction properties.
Materials and Methods
Materials. All chemicals and reagents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated. Tissue culture reagents were from Invitrogen (Paisley, UK H]inositol, and enhanced chemiluminescence reagent were from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Antibodies against total ERK1/2, phospho-ERK1/2, and horseradish peroxidaseconjugated secondary antibodies were from New England Biolabs (UK) Ltd. (Hitchin, Hertfordshire, UK). AC-42 and 77-LH-28-1 were synthesized in-house by GlaxoSmithKline (Harlow, UK).
Cell Culture. Chinese hamster ovary cells stably expressing the recombinant human M 1 mACh receptor (CHO-M 1 cells) were grown in minimal essential medium-␣ supplemented with fetal bovine serum (10%), penicillin (50 units ml Ϫ1 ), streptomycin (50 g ml Ϫ1 ) amphotericin B (2.5 g ml Ϫ1 ), and G418 (500 g ml
Ϫ1
). Cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 in air.
[ 3 H]NMS Binding.
[ 3 H]NMS inhibition binding assays were carried out as described previously (Mistry et al., 2005) . Specifically, CHO-M 1 cells were seeded at a density of 75,000 cells per well in 24-well plates. The next day, cells were washed three times with warmed Krebs-Henseleit buffer (KHB; composition: 118 mM NaCl, 4.7 mM KCl, 4 mM NaHCO 3 , 1.3 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 11.7 mM glucose, 8.5 mM HEPES, pH 7.4) before being transferred to an ice bath and 1 ml of ice-cold KHB containing appropriate concentrations of agonists and approximately 0.2 nM [ 3 H]NMS added. After a 5-h incubation at 4°C, cells were washed three times with ice-cold KHB before the addition of 0.1 M NaOH (500 l). After cell solubilization, 4 ml of SafeFluor scintillation fluid (PerkinElmer Life and Analytical Sciences, Groningen, The Netherlands) was added, and radioactivity was determined by scintillation counting.
Cell Lysate Preparation for Determination of ERK Activity. CHO-M 1 , -M 2 or -M 3 cells were seeded at 150,000 cells per well in 12-well plates 48 h before assay. Cells were washed twice and incubated with KHB for 1 h at 37°C. Drug additions were made directly to the KHB at the concentrations indicated (see figure legends) for 5 min. Incubations were terminated by transfer of the plates to ice and rapid aspiration of agonist-containing KHB. Cells were washed twice with ice-cold KHB before the addition of 150 l of SDS sample buffer (62.5 mM Tris/HCl, 2% SDS, 10% glycerol, 0.1% bromphenol blue, and 50 mM dithiothreitol, pH 7.4). Cells were scraped from the plate and transferred to centrifuge tubes. Cell lysates were sonicated for 20 s to reduce sample viscosity, boiled for 5 min, and then centrifuged at 20,000g for 1 min at 4°C.
Western Blotting Analysis. Cell lysate samples (25 l) prepared as described above were separated by 10% SDS-polyacrylamide gel electrophoresis by use of the Bio-Rad mini-gel system (Bio-Rad Laboratories, Hercules, CA). Proteins were electrotransferred to nitrocellulose membranes with use of the Bio-Rad semidry blotter apparatus according to the manufacturer's instructions. After transfer, membranes were blocked for nonspecific binding with 5% nonfat milk in Tris-buffered saline (50 mM Tris/HCl, 150 mM NaCl, pH 7.6) containing 0.1% Tween 20 (TBS-T) for 1 h at room temperature. Membranes were washed for 3 ϫ 5 min with TBS-T before incubation with the anti-phospho-pERK1/2 antibody (1:1000 in 5% bovine serum albumin in TBS-T) overnight at 4°C. Membranes were washed for 3 ϫ 5 min to remove excess antibody before detection with a horseradish peroxidase-conjugated secondary antibody (goat antirabbit, 1:3000 in 5% milk in TBS-T) for 1 h at room temperature. Membranes were washed 3 ϫ 5 min with TBS-T before chemiluminescence detection by use of enhanced chemiluminescence reagent (GE Healthcare) and exposure to film (Eastman Kodak, Rochester, NY). Equal protein loading was confirmed by submerging the membrane in stripping buffer (62.5 mM Tris/HCl, 100 mM 2-mercaptoethanol, 2% SDS, pH 6.7) and incubation for 30 min at 50°C. Membranes were then washed with TBS-T before reprobing with an anti-total ERK antibody and detection as described above.
Receptor Regulation Assay. CHO-M 1 , -M 2 , or -M 3 cells were seeded at 75,000 cells per well in 24-well plates for 24 h before being washed twice with warmed phosphate-buffered saline and incubated with serum-free medium at 37°C in a humidified atmosphere of 5% CO 2 in air. Drug additions were made at the indicated time points at 37°C (see Results) before cells were transferred to an ice bath and subjected to six washes with ice-cold KHB to remove the ligand. Cells were then incubated for 16 h at 4°C with either 3 nM [the total receptor population). In both cases, nonspecific binding was determined in the presence of 10 M atropine. At the end of the incubation period cells were washed four times with ice-cold KHB to remove unbound radioligand, solubilized with 2 ϫ 0.25 ml of 0.1 M NaOH, and transferred to scintillation vials. Samples were mixed with 4 ml of SafeFluor scintillation fluid before radioactivity was determined by scintillation counting.
[ 3 H]Inositol Phosphate Accumulation Assay. CHO-M 1 cells were seeded at 100,000 cells per well in 24-well plates for 24 h. Cells were washed twice with warmed phosphate-buffered saline and incubated for 48 h in serum-free medium containing 2.5 Ci ml
[ 3 H]inositol. Agonists were added to the cells for the last 24 h of the labeling period. Confluent cell monolayers were washed five times to remove ligand before incubation in KHB containing a final concentration of 10 mM LiCl for 30 min at 37°C. Agonists or buffer were added for 20 min before reactions were terminated by the addition of an equal volume of ice-cold 1 M trichloroacetic acid and transfer to an ice bath. After extraction (ϳ30 min) samples were neutralized by use of the Freon/tri-n-octylamine method and the [ 3 H]inositol mono-, bis-, and trisphosphate ([ 3 H]IP x ) fraction recovered by anion exchange chromatography with use of Dowex-1 (formate form) columns. Columns were initially regenerated with 10 ml of 2 M ammonium formate/0.1 M formic acid before being washed extensively with distilled water. Samples were washed onto the columns with 5 ml of distilled water. Columns were then washed with 10 ml of 60 mM ammonium formate/5 mM sodium tetraborate and the [ 3 H]IP x fraction eluted in 10 ml of 0.75 M ammonium formate/0.1 M formic acid. A 5-ml aliquot of the collected eluate was mixed with 10 ml of Ultima-Flo AF scintillation cocktail (PerkinElmer, Beaconsfield, Buckinghamshire, UK), and radioactivity was determined by liquid scintillation counting.
Data Analysis. All data are expressed as means Ϯ S.E.M. for the indicated number of experiments. Radioligand binding data and agonist concentration-response curves were analyzed by use of Prism 5 (GraphPad Software Inc., San Diego, CA). IC 50 values derived from agonist-[ 3 H]NMS competition binding experiments were converted to K B values by the method of Cheng and Prusoff (1973) . Statistical differences between multiple data sets were assessed by one-way analysis of variance followed by Bonferroni's multiple-range test at P Ͻ 0.05 with use of Prism 5 (version 5.5). 3 H]NMS in the presence of varying agonist concentrations at 4°C for 5 h (to achieve equilibrium binding without causing receptor internalization). The apparent binding affinity (pK B ) for each agonist is summarized in Table 1 . Consistent with previous reports, both AC-42 and 77-LH-28-1 are able to displace specific [ 3 H]NMS binding from M 2 and M 3 mACh receptors (Spalding et al., 2002; May et al., 2007; Langmead et al., 2008a ) with 77-LH-28-1 and AC-42 apparent affinities at the M 2 subtype being comparable with those observed at the M 1 mACh receptor (Table 1) .
Results

Determination of Agonist
Effects of Chronic Agonist Exposure on Cell-Surface and Total Cellular Levels of the M 1 mACh Receptor. The effects of a 24-h pretreatment with an orthosteric or allosteric agonist on the expression of the M 1 mACh receptor at the cell surface was investigated by use of a radioligand binding approach. Because of the limiting solubility of AC-42 and the potential toxicity of the dimethyl sulfoxide solvent/ vehicle, the maximum concentration that could be used in these experiments was 10 M AC-42, which results in approximately 75% occupancy of the M 1 mACh receptors. Therefore, the concentrations of all other ligands used were chosen to give an equivalent 75% receptor occupancy. Initial saturation analysis with (Fig. 1A) . The orthosteric partial agonists arecoline (30 M) and pilocarpine (35 M) also induced significant M 1 mACh receptor internalization (Fig. 1A) . Incubation for 24 h with the allosteric agonist 77-LH-28-1 (3 M) caused 32 Ϯ 5% (P Ͻ 0.05) internalization, whereas AC-42 (10 M) caused an insignificant (Ͻ10%) internalization of the cell-surface M 1 mACh receptor population (Fig. 1A) .
The internalized receptor can either be processed for recycling to the cell surface (resensitization) or degraded, resulting in a decrease in the total cellular complement of the receptor (down-regulation). To assess this, we used [ 3 H]QNB to quantify changes in the total M 1 mACh receptor population. Pretreatment for 24 h with the full agonist oxo-M (15 M) caused the greatest decrease in M 1 mACh receptor level (Ն40%, P Ͻ 0.05; Fig. 1B ). Of the other orthosteric or allosteric agonists used, only pilocarpine (35 M) pretreatment resulted in a statistically significant down-regulation. Again, It was noteworthy that, although 77-LH-28-1 caused at most a very small down-regulation (11 Ϯ 7%; P Ͼ 0.05), AC-42 actually caused an apparent (15-20%) increase in the total M 1 mACh receptor population (Fig. 1B) .
Similar, contrasting effects of oxo-M and AC-42 were also seen in a different CHO-M 1 clone with a lower human M 1 mACh receptor expression level (ϳ300 fmol mg Ϫ1 protein). In this cell-line incubation with oxo-M (15 M) for 24 h caused 53 Ϯ 5% (P Ͻ 0.05) and 35 Ϯ 14% decreases in cell-surface ( Time course studies were next performed to profile agonist-induced changes in M 1 mACh receptor expression both at the cell surface and in the cell as a whole. Pretreatment with oxo-M (15 M) caused a time-dependent monoexponential decrease in cell-surface expression of the M 1 mACh receptor. After 60 min of oxo-M treatment, 29 Ϯ 5% (P Ͻ 0.01) internalization of the M 1 mACh receptor population was detected ( Fig. 2A) . Oxo-M-induced M 1 mACh receptor down-regulation occurred more slowly and only reached statistical significance after 21 h of agonist treatment (P Ͻ 0.01; Fig. 2A ).
Arecoline (30 M) and pilocarpine (35 M) caused similar monoexponential patterns of M 1 mACh receptor internalization with their effects reaching significance early in the time course (after 1-3 h; see Fig. 2B ). Investigation of arecolineand pilocarpine-induced M 1 mACh receptor down-regulation revealed that each ligand was able to induce significant receptor degradation by 16 h (P Ͻ 0.01; Fig. 2C ). Despite their lower relative efficacies toward acute signaling events compared with oxo-M (e.g., [
35 S]guanosine 5Ј-O-(3-thio)triphosphate loading of G␣ q/11 , phospholipase C activation; see Thomas et al., 2008) , pilocarpine and arecoline caused comparable degrees of receptor down-regulation relative to the full agonist through the 6-to 24-h time period (Fig. 2C) .
In contrast to the orthosteric ligands, the profiles for AC-42 and 77-LH-28-1 regulation of M 1 mACh receptor internalization/down-regulation were notably different. Neither allosteric agonist caused receptor internalization over the initial 6 h of exposure (Fig. 2D) . Although 77-LH-28-1 did cause a significant M 1 mACh receptor internalization on prolonged exposure (37 Ϯ 7%, P Ͻ 0.05; loss of cell-surface receptor at 16 h; Fig. 2D ), AC-42 did not significantly affect cell-surface receptor expression at any time point studied (Fig. 2D) . Neither AC-42 nor 77-LH-28-1 caused a significant down-regulation of the M 1 mACh receptor; for both agents there seemed to be an acute increase in total receptor number peaking at 6 h (Fig. 2E) . Whereas for 77-LH-28-1 there was a subsequent decrease in total M 1 mACh receptor number (by 20 Ϯ 8%, P Ͼ 0.05; after 21 h; Fig. 2E ), the initial increase in receptor number (to 122 Ϯ 3% of the initial expression level at 6 h; Fig. 2E ) in the presence of AC-42 was maintained throughout the 24-h time course.
Stability of Orthosteric and Allosteric Ligands. The contrasting effects of orthosteric and allosteric agonists on M 1 mACh receptor internalization/down-regulation prompted us to assess the stability of each of the ligands used. Ligands were added to monolayers of CHO-M 1 cells (at the concentrations used in the studies reported above) and incubated for 24 h at 37°C. Medium from cell incubations and matched concentrations of each agonist freshly prepared in identical culture medium were added to myo- responses stimulated by each ligand were observed, indicating that all of the ligands used here are stable under the conditions used in the receptor regulation studies (Fig. 3) .
Antagonism of Agonist-Induced Receptor Internalization and Down-Regulation. To confirm that the observed changes in receptor internalization and down-regulation are mediated by M 1 mACh receptor occupancy we investigated whether the agonist-stimulated effects were prevented by preaddition of the mACh receptor antagonist atropine. Atropine (0.3 M) addition alone caused a small, insignificant increase in both (Fig. 5A ). These values are broadly similar to those obtained for oxo-M-stimulated changes in M 1 mACh receptors in the CHO cell background (see Fig. 1 ). Contrasting data were obtained for the allosteric mACh receptor agonists; whereas AC-42 (5 M) caused no change, the presence of 77-LH-28-1 (5 M) resulted in a 60 Ϯ 5% increase in cell-surface expression of the M 2 mACh receptor (Fig. 5A ). More marked adaptive changes in the total cellular M 2 mACh receptor expression level were observed after 24 h of treatment with either AC-42 or 77-LH-28-1. Thus, AC-42 and 77-LH-28-1 each caused, respectively, highly significant 179 Ϯ 2 and 100 Ϯ 6% increases in M 2 mACh receptor levels (Fig. 5A) .
The effects of chronic exposure to the allosteric mACh receptor agonists on M 3 mACh receptor expression were also assessed. As mentioned earlier, the solubility limits of AC-42 and 77-LH-28-1 are such that the maximum concentration that can be studied in chronic experiments is 10 M. At the M 3 mACh receptor it can be calculated that use of 10 M AC-42 will result in approximately 40% receptor occupancy (Table 1) . Pretreatment for 24 h with oxo-M (75 M, a concentration calculated to give approximately 40% receptor occupancy) caused 50 Ϯ 3% internalization and 23 Ϯ 6% down-regulation of the M 3 mACh receptor (Fig. 5B) . Pretreatment with either AC-42 (10 M) or 77-LH-28-1 (10 M) caused no significant changes in either cell-surface or total cell expression of the M 3 mACh receptor (Fig. 5B) .
Signaling Properties of AC-42 and 77-LH-28-1 at Human M 2 and M 3 mACh Receptors. Recent studies have reported actions of AC-42 and 77-LH-28-1 at non-M 1 mACh receptor subtypes (May et al., 2007; Langmead et al., 2008a) . Here, we have shown that both allosteric agonists can displace specific [ 3 H]NMS binding to the M 2 and M 3 mACh receptors (Table 1) . AC-42 and 77-LH-28-1 have been reported to act allosterically at the M 2 mACh receptor (May et al., 2007) , but a similar mechanism of action has not been reported at the M 3 receptor (Langmead et al., 2008a) . Oxo-M stimulated significant increases ERK1/2 phosphorylation (P Ͻ 0.001) via human M 1 , M 2 , and M 3 mACh receptor subtypes stably expressed in CHO cells (Fig. 6, A-C) . AC-42 and 77-LH-28-1 caused, respectively, 71 Ϯ 14% and 67 Ϯ 16% of the phorbol-12,13-dibutyrate-stimulated ERK1/2 phosphorylation response at the M 1 mACh receptor, consistent with their activation of other signaling pathways through this subtype (Thomas et al., 2008) . At the M 2 mACh receptor, neither AC-42 nor 77-LH-28-1 caused a significant increase in ERK1/2 phosphorylation at agonist concentrations that elicit significant activation via the M 1 mACh receptor (Fig.  6B) . At the M 3 mACh receptor, AC-42 was without effect, whereas 77-LH-28-1 caused a statistically insignificant increase in ERK1/2 phosphorylation, which was 20% of the response stimulated by phorbol-12,13-dibutyrate (PDBu) (Fig. 6C) . All orthosteric and allosteric agonist effects were prevented by preincubation of M 1 /M 2 /M 3 mACh receptorexpressing CHO cell-lines with atropine (300 nM) for 30 min.
Effects of Chronic Ligand Exposure on the Function of M 1 mACh Receptors. The lack of effect of AC-42 on M 1 mACh receptor internalization and down-regulation despite its ability to activate signal transduction cascades prompted the question of whether any index of receptor desensitization is altered by chronic exposure to this allosteric agonist. Perhaps the most relevant is to assess how prior treatment with AC-42 affects the ability of the M 1 mACh receptor to transduce agonist binding into a (functional) cellular response. To do this we used the [ 3 H]IP x accumulation assay with the (Fig. 7, Table 2 ). Pretreatment with oxo-M (15 M) or pilocarpine (35 M) resulted, respectively, in 68 Ϯ 2 and 44 Ϯ 14% decreases in the maximal [ 3 H]IP x response stimulated subsequently by arecoline (Fig. 7 , Table  2 ). In contrast, pretreatment with AC-42 (10 M) for 24 h did not decrease the maximal [ 3 H]IP x response to arecoline and was essentially identical to that seen in control CHO-M 1 cells ( Fig. 7; Table 2 ). These data are in excellent agreement with the previous data obtained from radioligand binding assays, and highlight the contrasting effects of AC-42 versus an equiefficacious orthosteric partial agonist (pilocarpine) on functional and radioligand-based receptor desensitization readouts.
Discussion
Despite the considerable therapeutic potential of drugs that can act selectively at mACh receptor subtypes, relatively few agonists or antagonists have been reported that possess a high degree (Ͼ10-fold) of mACh receptor subtype selectivity (Caulfield and Birdsall, 1998; Eglen et al., 1999; Langmead et al., 2008b) . The advent of new classes of drug that act via allosteric (as opposed to orthosteric) binding sites on the mACh receptor has provided new opportunities to 
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achieve subtype selectivity of action (Birdsall and Lazareno, 2005; Gregory et al., 2007) . AC-42 (Spalding et al., 2002) and its structurally related and more potent analog 77-LH-28-1 (Langmead et al., 2008a) bind to the M 1 mACh receptor at a site distinct from the acetylcholine binding site. Although initial studies with M 1 /M 5 mACh receptor chimeras suggested that AC-42 binding involves N-terminal/transmembrane domains 1 and 7 (Spalding et al., 2002) , a recent study by Hulme and colleagues highlighted roles for specific amino acid residues within transmembrane domains 2, 3, and 7, and proposed a "Trp (tryptophan)-flip" mechanism for M 1 mACh receptor activation by AC-42 and 77-LH-28-1 (Lebon et al., 2009) . AC-42 and 77-LH-28-1 binding to the M 1 mACh receptor initiate a number of cell signaling events, including phosphoinositide hydrolysis and Ca 2ϩ mobilization (Spalding et al., 2002 (Spalding et al., , 2006 Langmead et al., , 2008a . In addition, we have recently shown that AC-42 and 77-LH-28-1 (like orthosteric full and partial mACh receptor agonists) can activate M 1 mACh receptor-G q/11 and -G s -coupling, but, in contrast to orthosterically acting agonists, these allosteric ligands do not facilitate significant G i/o -coupling in the CHO-M 1 cell line used in the present study (Thomas et al., 2008) . These data suggest that there may be subtle differences in the receptor conformations stabilized by orthosteric and allosteric agonists, and this prompted the present investigation into whether AC-42 and 77-LH-28-1 cause comparable adaptive changes in the M 1 mACh receptor population to orthosteric ligands.
As in the vast majority of GPCRs examined to date, M 1 mACh receptor internalization involves phosphorylation, arrestin binding, and endocytosis via a clathrin-and dynamindependent mechanism (Ferguson, 2001; van Koppen and Kaiser, 2003) . The M 1 mACh receptor can be phosphorylated by a number of protein kinases, including G protein-coupled receptor kinases (Haga et al., 1996; Waugh et al., 1999; Willets et al., 2005) to cause acute desensitization. Evidence for arrestin (␤-arrestin1/2) involvement is presently inconclusive, but recombinant M 1 mACh receptors recruit endogenous ␤-arrestin2 (but not ␤-arrestin1) in RBL-2H3 cells (Santini et al., 2000) , whereas endogenous M 1 mACh receptor desensitization is increased in hippocampal neurons recombinantly expressing ␤-arrestin2 (Willets et al., 2005) . In addition, dominant-negative constructs of ␤-arrestin (V53D) and dynamin (K44A) inhibit M 1 mACh receptor internalization in human embryonic kidney cells (Vögler et al., 1999) .
Irrespective of the precise molecular mechanisms of M 1 mACh receptor regulation, the cellular location of mACh receptors can be monitored in intact cells by use of [ 3 H]NMS and [
3 H]QNB to quantify, respectively, cell-surface and total mACh receptor subpopulations (Maloteaux et al., 1983; Lameh et al., 1992) . This radioligand binding approach has been widely used to demonstrate that a variety of factors, including exposure to agonist, can alter the distribution and total number of mACh receptors present in cells (van Koppen and Kaiser, 2003) . In the present study, we have used a CHO cell background devoid of endogenous mACh receptors, and exposed CHO cells stably expressing human M 1 mACh receptors to orthosteric and allosteric mACh receptor agonists for periods of up to 24 h at concentrations calculated to give equivalent 75% receptor occupancy. The orthosteric agonist oxo-M caused a time-dependent decrease in [ 3 H]NMS binding that approached an apparent maximum (ϳ70% loss of cell-surface receptors) at 21 to 24 h. Time courses for pilocarpine-and arecoline-induced decreases in [ 3 H]NMS binding were similar in shape, but reached apparent maxima with more cell-surface M 1 mACh receptors remaining (see Fig. 2 ). In marked contrast, neither AC-42 nor 77-LH-28-1 caused any loss of cell-surface receptors in the initial 6-h exposure period. After 24 h cell-surface receptor expression was essentially 100% of the control value in CHO-M 1 cells exposed to AC-42, but had declined (by ϳ30%) in cells exposed to 77-LH-28-1. In a preliminary report, chronic (16 h) treatment with AC260584, another AC-42-series analog, also failed to cause M 1 mACh receptor down-regulation despite evoking a robust Ca 2ϩ response (Davis et al., 2005) . The relative lack of effect of the allosteric agonists was not attributable to compound instability, because bioassay (using the [ 3 H]inositol phosphate assay) revealed that 24 h of exposure to cells and culture medium did not compromise the biological activity of any of the agonists used in this study.
Internalized M 1 mACh receptors can either be dephosphorylated and returned to the plasma membrane or degraded van Koppen and Kaiser, 2003; Mosser et al., 2008) . Quantification of the total M 1 mACh receptor population (by use of [ 3 H]QNB binding) indicated that none of the agonists caused down-regulation during the first 6 h of exposure, and only oxo-M and pilocarpine caused statistically significant downregulations after a 24-h exposure period. Incubation of CHO-M 1 cells with AC-42 resulted in a modest up-regulation of the M 1 mACh receptor (see Fig. 2 ). In addition, whereas preaddition of atropine (300 nM added 30 min before agonist) completely prevented receptor internalization and down-regulation for the orthosteric agonists tested, 24 h of treatment with AC-42 in the presence of atropine caused significant increases in both the total (61 Ϯ 7%; P Ͻ 0.01) and cellsurface (51 Ϯ 3%; P Ͻ 0.01) M 1 mACh receptor populations. This represents a substantial quantitative increase in the cell-surface receptor population (approximately 2.5 ϫ 10 5 receptors per cell) over this time period. It is possible for this AC-42/atropine effect to be explained by a complex allosteric interaction, where AC-42 has positive cooperativity with respect to atropine in terms of efficacy, with the functional output in this case being a decrease in receptor internalization/degradation. Both AC-42 and atropine have been independently shown to increase cell-surface mACh receptor expression (May et al., 2005) , indicating that both are "agonists" with respect to this endpoint. Even if AC-42 and atropine are highly negatively cooperative with respect to binding (although this has not been directly measured here), if they exhibit a sufficiently positive efficacy cooperativity, then the decrease in constitutive receptor recycling mediated by atropine may be facilitated in the presence of AC-42.
Previous studies in the CHO cell background have shown that, in the presence of 300 nM atropine, [
3 H]IP x and Ca 2ϩ responses to AC-42 (10 M) are partially inhibited (by approximately 90 and 40%, respectively; see . Furthermore, have presented evidence that AC-42 and atropine can simultaneously occupy the M 1 mACh receptor, albeit in a highly negatively cooperative manner. However, these data were obtained by use of Ca 2ϩ mobilization as a functional measurement and to date there have been no studies investigating the interaction of AC-42 and atropine at the level of receptor regulation where the interaction may not be comparable. It is also interesting to note that chronic treatment of CHO-M 2 , but not CHO-M 3 , cells with AC-42 or 77-LH-28-1 (at concentrations adjusted to give equivalent occupancies of the M 2 /M 3 mACh receptor populations) also caused increases in the total cellular M 2 mACh receptor population and, in the case of 77-LH-28-1, a significant increase in cell-surface receptor expression (Fig. 6 ). Allosteric modulators of the M 2 mACh receptor have been reported to cause receptor up-regulation in a CHO cell background (May et al., 2005) . AC-42 and 77-LH-28-1 can bind to non-M 1 mACh receptor subtypes (Spalding et al., 2002; May et al., 2007; Langmead et al., 2008a) , but generally lack efficacy (but see May et al., 2007; Langmead et al., 2008a) (Fig. 5) . However, to date, no studies are investigating the consequences of occupancy by these allosteric agonists on receptor regulation, and it is possible that these ligands influence receptor regulation.
Our data indicate that chronic occupation of the M 1 mACh receptor by AC-42 and, to at least some extent, 77-LH-28-1 causes much less receptor internalization and down-regulation than in the presence of similarly efficacious orthosteric agonists, where studies have been specifically designed to match receptor occupancy levels by the different agonists. This conclusion is supported and extended by our observation that after chronic treatment with AC-42, the ability of an orthosteric partial agonist (arecoline) to stimulate phospholipase C activity is largely unaffected, in contrast to the marked reductions in maximal responses seen after chronic treatments with oxo-M or pilocarpine. It is interesting that a very recent report has shown, with use of a ␤-galactosidase complementation approach, that AC-42 does not cause significant ␤-arrestin recruitment to the M 1 mACh receptor in a CHO cell background (Ma et al., 2009 ). These and our data suggest that early events in receptor desensitization are likely to be spared during M 1 mACh receptor stimulation with AC-42 and perhaps other allosterically acting agonists. These data therefore suggest that, in addition to offering considerable potential advantage with respect to receptor subtype specificity and functional selectivity toward signaling readouts (Thomas et al., 2008) , allosteric agonists may induce receptor conformations less favorable to receptor desensitization/internalization programs than orthosteric ligands.
